Dear GRG Member,
Targeting/Taming Aging With Metformin (TAME) Study
Some high points of the article link below:
- Nir Barzilai, M.D., is the Director, Institute for Aging Research, Einstein College of Medicine and Scientific Co-Director of The American Federation for Aging Research.
- The main reason of the TAME study is to convince the Food and Drug Administration (FDA) to approve aging as an indication, and thus a target for future and even better medications.
- Barzilai and team hypothesize that delaying aging is the only effective way to delay age-related diseases and compress morbidity.
- Metformin is an FDA-approved drug and first-line drug of choice for prevention and treatment of type 2 diabetes (T2DM).
- Metformin extends the lifespan and healthspan in animals, and has shown positive effects in humans. There’s an association of metformin with decreased risk of cancer, as well as decreased cancer mortality
- TAME is a novel study that will recruit elderly subjects and, in a double-blind, placebo-control study, will test if metformin can delay the onset of multi-morbidities including cancer, CVD, T2DM, cognitive decline, and mortality.
- A number of experts are involved in the project, like Dr. S. Jay Olshansky and Dr. Jim Kirkland among others.
- Barzilai said “I was raised on the belief that it is possible to change the world (or part of it). Many have said it before and failed. But it doesn’t matter, you start again with a better plan. The difference today is that by creating collaborations, opportunities, and friendships with many others we have more than a village to succeed.”